Jim Cramer: Barclays' $29 Price Target on Valeant Is 'Very Right'

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer thinks Barclay's $29 price target on Valeant Pharmaceuticals (VRX) is "very right."

The stock rose over 4% Wednesday on the heels of the Barclays upgrade to $24.58 a share.

Valeant has cleaned up its balance sheet, according to Cramer. 

Want exclusive investing insight from Jim Cramer? Get 24/7 access to Jim's charitable trust portfolio with a free trial to Action Alerts PLUS!